TRK-IN-31
TRK-IN-31 is an orally active TRK inhibitor with an IC50 of 1.8 nM. TRK-IN-31 has superior antiproliferative activity in the Ba/F3-MPRIP-TRKAG667C cells, and potently inhibits TRK kinase activity with high selectivity. TRK-IN-31 significantly inhibits tumor growth in Ba/F3-MPRIP-TRKAG667C subcutaneous tumor mice model[1].
Product Specifications
UNSPSC
12352005
Target
Trk Receptor
Related Pathways
Neuronal Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
FC1=CC=C(C=C1[C@@H]2N(C3=CNC(C(C(NC4=CC5=C(C=C4)OC(C(N6CCN(CC6)C)=O)=C5)=O)=C3)=O)CCC2)F
Molecular Formula
C30H29F2N5O4
Molecular Weight
561.58
References & Citations
[1]Xu Z, et al. Structural Optimization of Next-Generation TRK Inhibitors against Acquired Drug Resistance Mutations for the Treatment of Solid Tumors. J Med Chem. 2025 Jun 12; 68 (11) :11484-11501.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Trk
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
K6550703 1.0 µg DNA
LOC691259 sgRNA CRISPR Lentivector (Rat) (Target 2)
Sign In for Pricing
View Details 
K2448706 1.0 µg DNA
TRBJ1-6 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1)
Sign In for Pricing
View Details